<DOC>
	<DOCNO>NCT01359254</DOCNO>
	<brief_summary>The primary objective study ass rate engraftment combine haploidentical-cord blood transplantation patient pre-existing donor specific antibody active disease .</brief_summary>
	<brief_title>Cord Blood Transplantation Patients With Cancer</brief_title>
	<detailed_description>Primary Objective - To assess rate engraftment combine haploidentical-cord blood transplantation patient pre-existing donor specific anti-HLA antibody active disease Secondary Objectives - To determine long term fate haplo transplant cord blood transplant setting . - To describe incidence severity acute chronic GVHD .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Relapsed refractory acute leukemia ( myeloid lymphoid ) Acute leukemia first remission highrisk recurrence Chronic myelogenous leukemia accelerate phase blastcrisis Chronic myelogenous leukemia chronic phase Recurrent refractory malignant lymphoma Hodgkin lymphoma Chronic lymphocytic leukemia , relapse poor prognostic feature Multiple myeloma Myelodysplastic syndrome Chronic myeloproliferative disease Hemoglobinopathies Aplastic anemia Zubrod performance status &gt; 2 Life expectancy severely limited concomitant illness Patients severely decrease LVEF impair pulmonary function test Estimated Creatinine Clearance &lt; 50 ml/min Serum bilirubin &gt; 2.0 mg/dl SGPT &gt; 3 x upper limit normal Evidence chronic active hepatitis cirrhosis HIVpositive Patient pregnant Patient guardian able sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>